Lytix Biopharma ASA (FRA:6BG)

Market Cap	69.78M +139.2%
Revenue (ttm)	n/a
Net Income	-5.07M
EPS	-0.07
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	250
Open	0.8820
Previous Close	0.8780
Day's Range	0.8820 - 0.8820
52-Week Range	0.4050 - 0.9740
Beta	n/a
RSI	46.98
Earnings Date	May 21, 2026

About Lytix Biopharma ASA

Lytix Biopharma ASA, a clinical stage biotech company, develops novel cancer immunotherapies for cancer therapy in the United States. Its lead product candidate is ruxotemitide, an oncolytic molecule that is developed for intratumoral injections, which is in Phase III clinical trials, to treat melanoma, basal cell carcinoma, and advanced soft tissue sarcoma; and NeoLIPA Phase II study in combination with pembrolizumab. The company also offers LTX-401, an oncolytic molecule in preclinical phase for the treatment of deep-seated tumors, such as he...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2003
• Employees: 14
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 6BG

Financial Performance

Financial numbers in NOK